NMDA Receptor Antagonists for Treatment of Depression
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Depression is a psychiatric disorder that affects millions of people worldwide. Individuals battling this disorder commonly experience high rates of relapse, persistent residual symptoms, functional impairment, and diminished well-being. Medications have important utility in stabilizing moods and daily functions of many individuals. However, only one third of patients had considerable improvement with a standard antidepressant after 2 months and all patients had to deal with numerous side effects. The N-methyl-d-aspartate (NMDA) receptor family has received special attention because of its critical role in psychiatric disorders. Direct targeting of the NMDA receptor could result in more rapid antidepressant effects. Antidepressant-like effects of NMDA receptor antagonists have been demonstrated in different animal models. MK-801 (a use-dependent channel blocker), and CGP 37849 (an NMDA receptor antagonist) have shown antidepressant properties in preclinical studies, either alone or combined with traditional antidepressants. A recent development is use of ketamine clinically for refractory depression. The purpose of this review is to examine and analyze current literature on the role of NMDA receptor antagonists for treatment of depression and whether this is a feasible route in drug discovery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 2×
“There are eight different GluN1 subunits generated by alternative splicing from a single gene, four different GluN2 subunits (A, B, C and D) and two GluN3 subunits (A and B); the GluN2 and GluN3 subunits are encoded by six separate genes [34,35,38].”
BackgroundNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Their findings indicate that the regulation of protein synthesis by spontaneous neurotransmission may serve as a viable therapeutic target for the discovery of fast-acting antidepressants [43].”
BackgroundNMDA receptor subunits: function and pharmacology
PAOLETTI, P., & NEYTON, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.011 · Cited by 887
Functional antagonists at the NMDA receptor complex exhibit antidepressant actions
Trullas, R., & Skolnick, P. (1990) · European Journal of Pharmacology · doi:10.1016/0014-2999(90)90204-j · Cited by 785
Papp, M., & Moryl, E. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90516-9 · Cited by 272 · cited 1×
“Their results suggest that antagonists of NMDA receptors may have antidepressant properties [44].”
BackgroundZomkowski, A. D. E., Engel, D., Gabilan, N. H., & Rodrigues, A. L. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.011 · Cited by 94 · cited 1×
“Their data suggest that the antidepressant-like effects of escitalopram is dependent on inhibition of either NMDA receptors or NO-cGMP synthesis [55].”
Background
Cited by
Molecular Mechanisms of Psilocybin and Implications for the Treatment of Depression
Ling, S., Ceban, F., Lui, L. M. W., Lee, Y., Teopiz, K. M., Rodrigues, N. B., Lipsitz, O., Gill, H., Subramaniapillai, M., Mansur, R. B., et al. (2022) · CNS Drugs · doi:10.1007/s40263-021-00877-y · Cited by 127
Lavretsky, H., Laird, K. T., Krause-Sorio, B., Heimberg, B. F., Yeargin, J., Grzenda, A., Wu, P., Thana-Udom, K., Ercoli, L. M., & Siddarth, P. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.08.011 · Cited by 61
Cardoner, N., Andero, R., Cano, M., Marin-Blasco, I., Porta-Casteràs, D., Serra-Blasco, M., Via, E., Vicent-Gil, M., & Portella, M. J. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230703091435 · Cited by 45
“…strategies such as ketamine, esketamine, and other antidepressant-like NMDA receptor modulators, have been linked with the pathogenesis of stress-related disorders and might have beneficial effects in preclinical and clinical studies for PTSD [292] MDD [293, 294] and anxiety disorders [295].”
Background(2014) · Europe PMC (PubMed Central) · Cited by 25
mGluR5 Facilitates Long-Term Synaptic Depression in a Stress-Induced Depressive Mouse Model
Jiang, X., Lin, W., Cheng, Y., & Wang, D. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719874162 · Cited by 18
“Recently, the role of NMDAR-LTD in pathogenesis of depression is under tremendous investigation due to the rapid effectiveness of NMDAR antagonist ketamine on depressive symptoms.(29) However, increasing evidence has shown that mGluR-LTD, the other major form of LTD, is also implicated in the pathogenesis of depressio…”
Background
Metadata
- Authors
- Ates-Alagoz, Z., & Adejare, A.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2013-04-03
- Volume
- 6
- Issue
- 4
- Pages
- 480-499
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2046489639
- Cited by
- 65
- References
- 8
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.